PubHawk
PLoS One January 2019 PMID 30153268

Long-term use of carvedilol in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention.

Hiroki Watanabe, Neiko Ozasa, Takeshi Morimoto, Hiroki Shiomi, Bao Bingyuan, Satoru Suwa, Yoshihisa Nakagawa, Chisato Izumi, Kazushige Kadota, Shigeru Ikeguchi, Kiyoshi Hibi, Yutaka Furukawa, Shuichiro Kaji, Takahiko Suzuki, Masaharu Akao

Download social card

Mentions

7
Peak: 1 in May 2023
across 4 sources since May 2023

Extended reach

2,643
potential audience

Total likes

17

Video views

593

Mentions per month

May 2023 – Nov 2025

Where it's discussed

  • News3 articles
  • YouTube2 videos
  • X / Twitter1 posts
  • Blogs1 articles

AI synopsis

What people are saying

The discussions reflect mild interest, with mentions like 'from a few years ago' and notes about recent trials, indicating a recognition of ongoing research but little detailed analysis or emotional investment, mostly providing factual updates.

AgreementNeither agree nor disagree

There is some cautious acceptance, as one comment notes that the study's conclusions remain valid over time, but does not express strong endorsement of the findings.

InterestModerate interest

Discussions show moderate curiosity, with a brief acknowledgment of a recent randomized controlled trial, indicating some engagement with new research but limited enthusiasm.

EngagementModerate engagement

The comments reference specific study types and past publication timelines, suggesting a basic level of engagement without in-depth analysis or debate.

ImpactModerate impact

The mention of the study's implications hints at relevance, but overall the discussions do not demonstrate that the findings are widely altering practices or opinions.

Abstract in brief

  • This study examined whether long-term use of carvedilol, a beta-blocker, improves outcomes for STEMI patients without heart failure or arrhythmia who undergo PCI, and found no significant difference in death, re-infarction, or hospitalizations over three years compared to no beta-blocker.
  • Despite being recommended by guidelines, the trial suggests that adding carvedilol long-term may not provide additional benefits in this specific patient group treated with modern, evidence-based strategies.
  • The results showed similar heart function (LVEF) and outcomes between the carvedilol and no beta-blocker groups, indicating that routine long-term carvedilol may not be necessary after successful PCI in uncomplicated STEMI cases.
Read the full abstract

Top posts

Most liked on X and Bluesky
Arden Barry
@ArdenBarry · X

@DrDeanElbe Done. It was from a few years ago, but I think the conclusions are still valid. There was this RCT published since then: https://t.co/T5IvfXyjuA

May 11, 2023 · 2,011 followers View post →

All mentions

Arden Barry
@ArdenBarry · X

@DrDeanElbe Done. It was from a few years ago, but I think the conclusions are still valid. There was this RCT published since then: https://t.co/T5IvfXyjuA

May 11, 2023 · 2,011 followers View post →
2024 ESC Guidelines For Themanagement of Chronic Coronary ...
News

PLoS One 2018;13:e0199347. J Am Coll Cardiol 1992;19:409–17. https://doi.org/10.1016/0735-1097(92)90499-D https://doi.org/10.1371/journal.pone.0199347 92.

Dec 13, 2025 View →
ehaf673 | PDF | Ejection Fraction | Myocardial Infarction
News

European Heart Journal (2025) 00, 1–15 – CLINICAL RESEARCH. https://doi ... 03.011 doi.org/10.1371/journal.pone.0199347 34. Cleland JGF. Staring into ...

Dec 13, 2025 View →
Is it time to deprescribe lifetime beta-blockers for chronic coronary ...
News

2018;doi:10.1371/journal.pone.0199347. Wilhelmsson C, et al. Lancet. 1974;doi:10.1016/s0140-6736(74)90807-1. Yndigegn B, et al. N Engl J Med ...

May 23, 2024 View →
2023 ESC Guidelines for the management of acute coronary ...
Blogs

https://doi.org/10.1371/journal.pone.0187662. 85. Boeddinghaus J ... 0199347. 806. Rossello X, Raposeiras-Roubin S, Latini R, Dominguez ...

Dec 26, 2023 View →